1408 episodios
- In part two of this series, Dr. Stacey Clardy talks with Drs. Jeff Ratliff, Andy Southerland, and Jason Crowell about memorable podcast interviews, the value of human connection and practical clinical education, and the podcast's evolution over the years.
Read the related article in Neurology®.
Nominations for the 2027 Ted M. Burns Humanism in Neurology Award will be open until December 18, 2026, at 3:00 pm CT.
Disclosures can be found at Neurology.org.
_______________________________________________
Dr. Jose Merino:
This is Jose Merino, editor-in-chief of the Neurology family of journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening and have a great week.
Dr. Stacey Clardy:
Hi, this is Stacey Clardy from the Salt Lake City VA and the University of Utah. Today, we're back with part two of our 20th birthday of the Neurology Podcast discussion with Andy Southerland, Jason Crowell, and Jeff Ratliff. We got talking, can you imagine it, the four of us? It turned into a long discussion, and so today is part two. Take a listen to the first episode. It'll make a lot more sense if you do that. I hope you enjoy the discussion.
All right, I want a favorite from each of us. So what's an interview you still think about that you conducted, Jason?
Dr. Jason Crowell:
Yeah, someone ironically, the one that always comes to my mind is back in 2020, I interviewed Sonia Vallabh, which you all may remember. She is a scientist in Boston. She is very smart. She graduated from Harvard Law School and had a career. And then in 2010, her mother developed fatal familial insomnia and passed away. And then it was found that she had this epigenetic etiology and then Sonia was tested, and she had inherited this mutation, and she and her husband took it upon themselves to try to figure this disease out and try to come up with a cure. And so they went back to school and graduated in biomedical science and were working at the Broad Institute when I interviewed her. And she just has an incredible story. She's incredibly eloquent. And to hear her speak to her family's experience of having her mom suffer from this disease and then the knowledge of this mutation and then her decision to do something about it is just incredibly impactful and really inspiring for someone to go through this and make up their mind that they're going to do something about it.
Dr. Stacey Clardy:
And as you know, we just recently had both of them back on because they're now in clinical trials. They have a trial in NeuroNEXT for prion disease and the ability to follow those stories over years on the podcast is also something remarkable because we've always had the editorial freedom to do that from all of the editors-in-chief of Neurology. If it's relevant, if it matters, it doesn't have to be published in a particular journal. It should be featured. We've always been encouraged. If it matters to neurologists, then we should cover it. And that was a perfect example of that and how we can continue to follow up and stay on top of particular stories of tremendous meaning to our field. What about you, Jeff?
Dr. Jeff Ratliff:
Even before I share this, we were just talking about what's the value of having the conversation with an author or with an individual, the value of a podcast, and what can come through in those conversations. And so my episode that sticks with me was actually getting to interview Avi Nath after he was awarded the Ted Burns Award for Humanism in Neurology. And it was in 2024 and listeners of the podcast had gotten to hear Avi's voice as we were going through the pandemic and talking about the neurologic implications of COVID-19. And he was so critical in teaching our listeners at that time. But in 2024, that interview was really about him and giving him a chance to reflect on his career as someone you could look at his website, you can look at PubMed, and you can see contributions that he's had to science in neurovirology.
But to hear him talk about being at the bedside of patients with HIV in the '80s when there was so much stigma associated with people with HIV at that time and how important it was to him to take care of patients and to not just learn about their disease, but to care for the people with the disease. And I remember that approach and that Avi's had a tremendous impact on neurology as a scholar, but hearing about that sort of humanistic physician-to-patient approach that informed his science and informed his career was really meaningful to hear about. That's a thing that, as you've already said, Stacey, it's hard to put that through in a publication in a paper. We have the privilege to hear those stories when we have conversations with people.
Dr. Stacey Clardy:
I agree. And I have two, I don't know if I would say favorite, but interviews that I knew were changing me while I was conducting it, so incredibly impactful. The February 7th, 2022 one where I was able to interview Dr. Daniel Drubach about his experience diagnosing his own Lewy body dementia. And Daniel Drubach, of course, is both a cognitive and psychiatry-trained neurologist working, had just recently retired at that time from the Mayo Clinic. And with his expertise, the ability to describe again what our patients were experiencing as he stepped through each part of that journey was incredible. And then also as part of that, thanks to our great editing staff, we were able to incorporate his music because he's an incredibly talented musician. And so that ability, again with audio to even further the story, while I was conducting that interview, I just was overwhelmed. The learning, the emotion, the humanity of it all.
And then I would say the other interview, which was challenging was December 27th, 2021 for the journal's 70th anniversary. And we're of course now in the 75th anniversary, but at that time, it was the 70th anniversary of the journal. And so we were interviewing past editors-in-chief and putting together that story. The Neurology team wanted to incorporate the podcast. And so I was able to interview Ted. And so the assignment was talk about the podcast and how it is an integral part of what the journal does.
The unspoken part of that interview though, in 2021, both of us knew this was a chance for Ted to give his voice to the podcast story for the last time. You can listen to that interview at about minute 17, part two in December 2021. And we just included a small snippet at that time, but that interview was very long. It was very hard because we knew we were recording the history.
And so very hard to do both of those interviews, but wouldn't have changed those opportunities for the world. But what all of us are getting at is both the privilege, but the incredible pressure of being a part of someone telling their story in real time and trying to steward it.
And Andy, I guess you kicked us off, but do you have any other favorites?
Dr. Andy Southerland:
There are a lot of great interviews over the years reference to the opportunity to interview people who are leaders in the field, and that's always exciting. I'd say that one of the coolest things about being part of the podcast though, and we've each talked about it a little bit, was just that the podcast really does cover the broader humanity of neurology. And Ted was really big on that. He would always say, "Tell me one thing you've learned about neurology today, but also tell me one thing you know that is not necessarily about neurology." And so he wanted us to interview human interest stories that were neurology-adjacent.
And probably one that sticks out to me, I still think about it all the time actually, is I had a chance to interview the novelist, Puerto Rican novelist Esmeralda Santiago back in 2014 who had herself suffered a stroke that affected her Wernicke's area of the brain, and she had a pure alexia and some receptive aphasia. And she had taught herself to read again, both in English and Spanish, and to write again, and she actually had published a novel after her stroke. And Ted heard about it, and we connected with her. And he allowed me to do the interview, and it was just amazing, and I encouraged folks to go back and listen to that interview. And she still is writing today. And I think about it all the time with my patients who have aphasia and are trying to relearn those same skills. And we talk about it with students and residents about folks that are multilingual and how that affects their language abilities. And that one sticks out in my mind as it were.
Dr. Stacey Clardy:
That's a great one. And of course, we make all of the episodes sound so seamless, but time to fess up. So Jason, I'm going to start with you. What is the funniest thing that's happened while you were trying to record an episode?
Dr. Jason Crowell:
So Ted had this idea, it was like 2018 or 2019. I'm not sure what sparked it, but he had this idea that we should go back and find every neurologist or neuroscientist who had been awarded a Nobel Prize and invite them to be on the podcast. I said, "Okay." And so we sent emails and Stanley Prusiner, recipient of the 1997 Nobel Prize at UCSF said he would come on. He, of course, discovered prions and I was nervous for this. This is a big one. This is Stanley Prusiner, Nobel recipient. And so I had my notes ready, and we start recording, and I was trying to just improvise on the spot and make it sound conversational. I was like, "Tell me, how did you decide to go into this field of prions?" And he was just not disrespectful. He was just like, "I didn't. It wasn't around. I came up with it." He wasn't being boastful, but I portrayed him as choosing to go into this field that didn't exist because he discovered the thing. So I wish I'd worded that one differently.
Dr. Stacey Clardy:
Oh, that's great. And I remember I was able to do one with Peter Doherty, and I remember ahead of it being explicitly told, "This is no different than every other interview that we do. And so you will call these folks by their first name." Talk about wildly uncomfortable. I mean, it's bad enough when you're, say, a trainee or junior faculty like we were, but then to just get onto this podcast, be like, "Hey, Peter." But of course, the lesson there was these are real people and they do just want to have a conversation. But I crack up every time we have a new interviewer and they struggle with the same thing when I'm going back and editing and I have to edit out 14 or 15 times when they're saying Doctor instead of the first name. And I always think of just chatting it up with the old Nobel laureate. It's a great one. How about you, Jeff?
Dr. Jeff Ratliff:
So this one involves Jason, and I'm glad he didn't take this story away from me. During the height of the pandemic, we were working on a two-part series about movement disorder emergencies, and Jason and I were taking turns interviewing each other and had built a script up. But for context, this is the year 2020. We are all at home. I have a two-and-a-half-year-old running around the house. It's July, and we couldn't quite get the reverb on the audio to go away in the office in my house.
And so finally, the solution that I had to resort to was grabbing a blanket and throwing it over my head, over the microphone, over the laptop while I'm talking to Jason. And so we're talking there about movement disorder emergencies, and I am sweating onto everything. It's just I'm uncomfortably warm. And Jason had some great banter. I still remember it, but it was another moment to be thankful that it's an audio-only medium because there was nothing aesthetically pleasing about that video experience if we had to subject ourselves to it.
Dr. Stacey Clardy:
Oh my goodness. Yes. I remember at some point, adding in an introduction to say, "Hey, listen, the audio's essentially really going to take a dive in these coming months. We don't know for how long." But yeah, we had worked so hard to perfect the audio, pandemic comes along, and you under a blanket and so many of the people we are interviewing in just hilarious positions. Andy, do you have a particularly fun memory of things going perfectly well?
Dr. Andy Southerland:
It's great to hear Jeff tell the story of a podcast interviewer's life. Surely the show must go on. And the beauty of podcasting is you can do it from anywhere as long as you've got good audio. And so not necessarily a story of something gone wrong, but I know I had to do a podcast interview early on one time, and it happened to coincide with my brother at the time was getting married and we were on a golf trip. And I remember specifically on the golf course having to step over into the snack shack that was the halfway house at a golf course. I won't say which one because that's probably some branding issues we'd have. And I did a podcast from the men's bathroom at the halfway house on the golf course. I won't even say who I was interviewing at the time. But I have to say when I went back and listened to it, other than a mild echo and occasional "Fore!" in the background, the audio [inaudible 00:12:55], and it wasn't a birdie, but it was a solid par that day.
Dr. Stacey Clardy:
Oh my goodness. And we should probably acknowledge here that there is a keeper of all our secrets who really we view as essential and we know we can't function without, but that's Anna Rehbein. She's even on this discussion. She's running it. She's keeping us in order. Anna, I want to put you on the spot. What have you had to do? Because really when things go terribly wrong and we can't fix it, we text Anna or call her or just throw our hands up. Anna, tell us your experience.
Anna Rehbein:
I remember sitting in on my first podcast recording when I got the job four years ago, and it just not going well whatsoever. There was a terrible echo. And going along the lines of Jeff's story, I had to ask somebody that was very high up at an organization, very well known in the field to ask them to go sit in their closet to do the recording, and I just felt so bad. I was like, "Oh my gosh, they are not going to want to come back onto the podcast." And at the end, they were so grateful for the opportunity and we've had them back on the podcast since. But I remember thinking, "Oh my gosh, I'm going to lose my job. This is the second week on the job."
Dr. Stacey Clardy:
Yeah, it needs to be done. Ultimately, that's the same thing as interviewing all these very famous people. They also want to sound good.
And along the way with the podcast changing format, changing segments, one of the fun things that everyone on this call was involved in was right around 2018 and into early 2019, we were looking at the world around us and seeing that there were home devices, smart devices, cars where you could open up your door, turn on the ignition and then say, "Give me my news." And out of that spun the discussions of we really need to have a way to utilize that time. So the Neurology Minute daily briefing, right? So we will always have a need and everyone will always love a long-format podcast, but the discussions began to center on other ways to get people the neurology information they need depending on their lifestyle or that era of their career.
Jason, tell me what you remember inspired the idea, what your recollection is of how the Neurology Minute daily briefing came to be.
Dr. Jason Crowell:
Yeah, Stacey, that's a good question. I've been trying to do some digging to sort out where this started. It's deep in my text thread with Ted going back in 2018. I can't remember whether it was him or me or his brother, but he had this idea that this was how we were going to consume news, and he looked ahead and saw that this is going to become increasingly compatible with our cars, with our computers, that these home devices would become increasingly popular. And so he really felt passionately about adapting and to what Andy said earlier about not becoming stale, about adapting to the times and making sure that we were providing content in the most digestible way.
Does anybody remember? Jeff, do you have any recollection specifically? I was going through my text thread, and there's several texts with you and Ted about daily briefings and listening in the car. I'm curious if you have any recollection.
Dr. Jeff Ratliff:
I absolutely remember the car being essential. And Ted would say this about the podcast and then about the Minute was that time when we are commuting to work, home from work is a time that we can fill. We can be a part of someone's daily habit of driving into work and they fire up, "Give me my ..." whatever news source you want for a daily update, but to have Neurology be a part of that. And I remember him sharing articles about, "Hey, look, this car's coming out and it's going to have this virtual assistant sort of built into it. And this is our chance. We got to get into the car, get into the ears of our listeners while they're fighting traffic between their homes and clinic or in the office."
Dr. Stacey Clardy:
And I remember the fun of getting to see Ted have the moment I had heard about from back in the beginning of podcasting era. He said, "Look, I don't know how this Minute is going to go and be used in five or 10 years. I just know we need to do this now. We need to make this accessible." And in my mind thinking, "Yeah, because I remember you talking about podcasts when I didn't know what an iPod was. So I'm kind of going to go with you on this one because you're right." I don't know if you remember anything similar, Andy.
Dr. Andy Southerland:
I was also going back and trying to dig, and I do remember specifically all of us being on a group call and bouncing this idea around. It really did, like all of the innovation that happened over time, I think spark was sort of Ted's desire just to be as accessible as possible to the folks that were listening to it. We were talking earlier about this, and I do remember correlating it at the time with another radio offering that was out on public radio called The 90 Second Naturalist, and you would go on and you hear a brief blurb every single day about something in the natural world, like a platypus or something. And then I remember us saying we're going to be The 90 Second Neurologist, and then ultimately, the Neurology Minute came out. And I also found the very first email from Jason with lots of exclamation points from February 15th, 2019 saying, "The Neurology Minute is now live."
And so all that provenance goes back to that time. But again, Ted had the ability to see things before they would happen, and he was annoyingly right most of the time, and this was one of those examples.
Dr. Jason Crowell:
I often think back to something that was said at Ted's funeral by, I believe it was Jeff. It was one of his brothers. And he was making the point about Ted that he always found empty spaces and created things there. And that was true about the podcast, that was true about the Minute, that was just true about Ted in general. He always had this vision of not taking things for what they were, but seeing where he could create something new or fill some void that needed filling.
Dr. Stacey Clardy:
Yeah. And it's exciting to watch the Minute. I know from many folks who listen to it who tell me, "Listen, I have a confession. I really still listen to it like a podcast. I haven't figured out the home device thing yet. I don't know how to program it so that I can say, 'Give me my news,' and it'll come." But I think it's continuing to evolve and it's a fun thing to watch.
I guess along that line, we ended the article by looking ahead. Jeff, if we're having this conversation again in 10 years, what would you love for us to have tried?
Dr. Jeff Ratliff:
As we look back, the platform the podcast is on has changed. You already told the story that at first, it was an iPod, and then obviously, we had iPhones, and that's pulling things together and giving us our podcasts. And I don't have the future vision that Ted had a gift for, like Jason just talked about, but there's going to be a platform and it may be an AI platform. And I don't know if Andy, you have sort of thoughts about how are we going to get audio and educational audio into our ears as we look ahead. The platform is what has changed. The content is what's been relatively consistent over these past 19, 20 years.
Dr. Andy Southerland:
Yeah. If you had asked me when we started doing this 20 years ago, if we'd still be doing it in an audio format like this, I would've probably tried to come up with some futuristic vision of something else it would be despite all the changes that have been made over time. It's hard to ignore the impact that AI is going to have on ... It is having currently as we sit here and talk and will continue to have 20 years from now on the way that we practice medicine. I can imagine a time when there'll be more integration with virtual reality in the practice setting and whether or not people would get their news or learn or information vis-a-vis that as an ultimate platform or as an end user.
But probably most important to me is that the podcast offers something to neurologists that is quintessential in this AI world. And again, it gets back to something we've all commented on today, which is the human aspects of, one, being a neurologist, sort of the breadth of what it means to be a neurologist, the humanistic components of being a neurologist, but it also connects us as human beings through technology. And that's what Ted always realized about it. Yes, we were interviewing authors of papers, but it brought that human connection. There's going to be a continual yearning for that as we are further separated vis-a-vis technology in this AI world. The demand for the way that we're communicating as professionals, as colleagues, as humans is only going to increase and the podcast is going to have staying power because of that in my estimation.
Dr. Stacey Clardy:
I couldn't agree with you more. I feel it acutely already when I'm using ChatGPT or whichever agent I'm using. Once I'm done doing that, I come out of those sessions desperately craving real human connection and real opinions. And that is the secret sauce of the podcast from the beginning. Many podcasts have come and gone in the time the Neurology Podcast has been around, but it's really the people who come onto the podcast are part of the secret sauce.
Jason, what do you think is part of the secret sauce in your estimation?
Dr. Jason Crowell:
I would add the laser focus that Ted always had on trying to make things clinically applicable and useful. He wanted us and you've done an excellent job at maintaining a focus on educating and making neurologists better neurologists. Whoever it is that's listening to this, you can come away with something that might help you in the next exam room, might help on rounds.
Dr. Stacey Clardy:
Jeff, do you have any thoughts?
Dr. Jeff Ratliff:
No, Jason nailed it. And I say the same thing and it's that voice of if we can make the neurologist better and getting past ... It doesn't have to necessarily be a scientific article. It doesn't have to be a clinical trial. It might be, as we've already talked about, a human interest story. It might be something that's happening at a governmental policy level, but there's so many things around us that have an impact on what we do between the four walls of the clinic. And we've all realized that we have this opportunity to take those stories and deliver them to listeners and hopefully they take something from it to what Jason said, to give them a new skill, a new piece of knowledge they can bring to a patient or to rounds.
Dr. Stacey Clardy:
Yeah. Couldn't say it better than you guys. Of course not. Andy, Jason, Jeff, thank you. It's been fantastic to have a chance to do this together, spend some time celebrating 20 years of the podcast, and of course, along with that, founder Ted Burns. And what we didn't really focus on too much, thanks for Anna letting us put you on the spot briefly, but really the many contributors. And we actually have compiled a list of the entire dedicated village from over the years. That's in the paper. If you want to look and see just how many people have given so much time to the podcast, that paper is titled From the Mailbox to the Microphone: The Neurology Podcast and the Evolution of Medical Education in Neurology.
Another thing that we haven't necessarily said, but I really hope everyone understands is this has been a highlight for all of us to be a part of. Everybody's always welcome to join, and it's really all of us feel acutely that we're just trying to steward this along. It belongs to the entire neurology community, and we all hope that you feel that every time you tune in.
Dr. Andy Southerland:
Well, Stacey, first and foremost, like you said, there have been myriad people over the years, not least of which are all the people who have allowed us to interview them and themselves interviewed folks over time and regular contributors of podcasts, but there are a couple of key people and Ted, again, to honor his legacy, would really want us to mention. And obviously they're the editors of the journal of Neurology, beginning with John Nosworthy, who took a flyer on this idea from Ted at the origins. And then Bob Gross really helped lead the journal during the heyday of the podcast taking off, and then the continued support from Jose Merino today. The folks at the journal, again, that were supportive, you got to mention Patty Baskin, Kathy Pieper, other people that support-
Dr. Stacey Clardy:
Sandy Moriarty. Yeah.
Dr. Andy Southerland:
Yeah. And I was just going to say the person that probably is most responsible for the original success, early-day success of podcast was actually Sandy Moriarty, who somehow drew the short straw as the staffer of the AAN who stuck with Ted as his original senior production editor. Sandy was the one who was able to take all of Ted's ideas and actually get them scheduled. And somewhere today, hopefully, Sandy is listening to this.
Dr. Stacey Clardy:
And now of course, Anna, and we didn't actually mention Adam Voorhees. Throughout every podcast we always do, every single one's been trimmed out, we will constantly interrupt and say, "Whoops, Adam, please cut that out." And so he's doing a lot of it and we've had many sound editors, Rima, others, Justin, over the years as well. Yeah, can't thank the village enough.
This is Stacey Clardy, your podcast editor. If you've enjoyed the podcast, please take a few moments to subscribe, rate, and review the Neurology Podcast through Apple Podcasts, Google Podcasts, Spotify, or wherever you listen. And remember, you can always head to neurology.org/podcast for our full list of past episodes, or you can also search by keyword in your podcast app for any neurology-specific topics you want to learn about. - In part one of this series, Dr. Stacey Clardy talks with Drs. Jeff Ratliff, Andy Southerland, and Jason Crowell about the evolution of the Neurology® Podcast, from Ted Burns's founding vision to the conversations and formats that have connected with listeners for nearly two decades.
Read the related article in Neurology®.
Nominations for the 2027 Ted M. Burns Humanism in Neurology Award will be open until December 18, 2026, at 3:00 pm CT.
Disclosures can be found at Neurology.org.
________________________________________________
Dr. José Merino:
This is José Merino, editor-in-chief of the Neurology family of journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening and have a great week.
Dr. Stacey Clardy:
Hi, this is Stacey Clardy from the Salt Lake City VA and the University of Utah. We are featuring a two-part series today. I'm joined by Jeff Ratliff, Andy Sutherland, and Jason Crowell. We're celebrating 20 years of the podcast and discussing everything that happens behind the scenes, what goes into it, and what really matters and has allowed for success over 20 years. We ended up talking, we got going, and it turned into a really long interview, so it will be broken into two parts. This is part one, and we'll start now with the beginning of the discussion.
The four of us, along with AAN and Neurology staff, recently researched and wrote an article in Neurology. We titled it, From the Mailbox to the Microphone: The Neurology Podcast and the Evolution of Medical Education. It gave us a great chance to revisit 20 years of podcasting as part of the even greater milestone, which is the 75th birthday of the Neurology journal.
So Andy, Jason, Jeff, this is a first, but it's great to have you all here together.
Dr. Jason Crowell:
Thanks, Stacey. Thank you for coordinating.
Dr. Andy Southerland:
What a group. Thank you, Stacey, for having us.
Dr. Jeff Ratliff:
Yeah, it's great to be here.
Dr. Stacey Clardy:
I want to understand your experience with the podcast. We've all had unique experiences and really understand what the last 20 years have been like through your memories.
So let's start with you, Andy. I want you to take us back to Ted Burns, the podcast founder at UVA. John Noseworthy invited him to lead the journal's podcast after hearing his work with AANEM, and the first episode then followed in September 2007.
And I would be remiss if I didn't take this opportunity to announce that the Ted Burns Humanism and Neurology Award is now accepting applications for 2027. You can find the link to nominate in the show notes. It's also if you go to the americanbrainfoundation.org/tedburns, you will find the announcement and how to nominate someone who manifests humanism in our field.
So what do you remember about how Ted got people excited about this and how did you get pulled into this?
Dr. Andy Southerland:
First of all, Stacey, it's amazing to me that in this upcoming year, it'll be 20 years that we've been doing the Neurology Podcast. As you said, the first episode aired in September of 2007, and this time next year we'll surpass that 20-year mark.
And what I remember about it is in 2007, I was a PGY-2 neurology resident here at the University of Virginia, and Ted Burns was my residency program director. And he had been talking about the idea of podcasting, and mainly because his residency, Ted viewed it as a new way to help us be educated, to give us readily available access to listening to world experts in the field of neurology, talk with other experts. It's hard to imagine, but back then I didn't know what a podcast was. Not many of us knew what a podcast was in 2007. And Ted really got his start in two ways.
One, you referenced he began doing an audio cast for AANEM. Ted was a neuromuscular neurologist and he developed an educational audio cast for that organization.
And the other provenance of the neurology podcast vis-a-vis Ted's vision, interestingly enough, came from his love of wine. Ted and some of his buddies started a wine and porting company. And by virtue of that, in addition to talking about neurology, Ted wanted to talk about his other favorite subject, wine, and started an audio cast called Grape Radio. I kid you not. And not only was that a popular wine audio cast or podcast at the time, but Ted was a finalist for a James Beard Award for media as it related to food and wine. I think the year that Ted was a finalist, while Martha Stewart and her television program actually won the James Beard Award that year for food and wine media.
But anyway, so the neurology podcast has deep roots both with Ted and his mentorship over us, but also proverbially in the roots of the vineyards here in Central Virginia in some ways.
Dr. Stacey Clardy:
That's wild. And actually I'm now looking at the dates and hearing you talking. And I interviewed at UVA for residency and it was actually later in 2007. I guess at that time he was already talking about it and working it into residency interviews. I'll never forget it. And he was so enthusiastic about it. I didn't even own an iPod. And when I think back on that, it stuck with me. That conversation as an applicant interviewing at a program was really how I was introduced to podcasts.
Jeff, what's your memory?
Dr. Jeff Ratliff:
My memory, I was also at the University of Virginia. So in this universe of Ted and the podcast, and I remember there was two things Ted would say over and over again. And he would say, "Listen to the podcast. I'm spoonfeeding you knowledge, and drink Williams Corner Wine." He had some skin in the game on the second one and there might've been a conflict of interest there, but yeah, it was baked into the culture.
I was at UVA a little bit after Andy finished his training and Andy was still around, but it was baked in and I would hear Andy, I would hear residents ahead of me doing interviews and then I got envious. I was like, "I want to do that. I want to do that." And would ask Ted, "Hey, if there's a good topic or if there's a good interview, keep me in mind, I'd love to get involved." And that was how I got involved when I was a resident there in Charlottesville.
Dr. Stacey Clardy:
Great point. That's still how it's done. We love when people volunteer, raise their hand and say they want to be involved. Jason, how did you get roped in?
Dr. Jason Crowell:
I guess I was first exposed being on consults with Ted and he would pull us into the resident room and we would've had another consult for confusion and someone in the ICU and he'd be like, "Man, we had a really great two-parter on workup of encephalopathy." And he would tell the medical students to pull it up and listen to it. And so again, it was baked into the culture, as Jeff said.
I was finishing my residency in 2017 and Ted had been encouraging me to do an interview. And so I was selected to do an interview with Nicholas Johnson now at VCU, to talk about a health policy act that had been put into place in Congress. And I remember being so nervous and I was so anxious. I can still remember sitting in the resident workroom in the basement of the clinic. And one of my other residents was in there and I jumped on the call, and it was done in four and a half minutes.
There was no banter. You would think that I had just done a live shot on cable news. And I got off and she was just like, "Was that it?" "I think so. I think that was it." So that was one of the first lessons that I really took away was you know it in your head that it's not live, but man, it feels live. Our audience doesn't even know right now, but I'm doing my third take of this very answer to your question and nobody knows because it's not live. You can just do the edit over and over again. That was key for me to improve my skill as an interviewer, was remembering that the editing can take care of a lot of it.
Dr. Stacey Clardy:
Although back then the editing was not what it is now and it was on phone lines. So yeah, there was a bit more pressure. And Jeff, your first interview I'm sure was amazing.
Dr. Jeff Ratliff:
My first interview, I still remember it. And it's actually cool to look back. My first interview was, it was April of 2014 and it was with an author named Vincenzo Donadio, and we were talking about doing skin biopsies of nerves to look at alpha-synuclein in the skin, which is crazy because if we think about topics we've featured just in the past few years about skin biopsy, biomarkers and Parkinson's. And so that was actually my first interview and it was on a landline, probably in the same office that Jason was in, and the connection was not good. He was in Italy and I was straining with every muscle in my ear to hear every bit I could hear of his answers.
And I remember Ted looking at my script beforehand and saying, "You're trying too hard. You're trying too hard. Keep it simple." And that lesson too of just ask the questions that the listener wants to hear the answer to. And that lens and that framework was the approach that we still think about now. But yeah, I was convinced Ted was never going to let me near his podcast again after that first interview. So I'm lucky to be here talking with you guys now.
Dr. Stacey Clardy:
Yeah, I remember always the gentle feedback. He was pretty good with the sandwich.
Andy, I didn't listen to your first interview. I assume there was some dad joke in there.
Dr. Andy Southerland:
I probably developed my comfort with sharing the puns that were going on in my head with the wider audience over the years, Stacey. But I actually had to go back and look and see actually what was my first interview with the podcast. And it's actually really interesting because it speaks not only to the educational quotient that we've all talked about in our time mentoring under Ted, but my first interview was in August of 2009. And I was asked to interview or given the opportunity by Ted to interview Pooja Khatri, who many people out there listening will recognize as the current chair of neurology at Yale University, who was a longtime vascular neurologist strokeologist at University of Cincinnati and PI of practice changing clinical trials. But at that time, there was an article that she and her team at Cincinnati published in the Neurology journal, and I'll tell you the title because it's meaningful, Good clinical outcome after ischemic stroke with successful revascularization is time-dependent.
And that is a concept that we know to be self-evident today. And it was based on data from the original interventional management of stroke in the vascular trials, predating, of course, all the eventual trials that showed that endovascular therapy for stroke was a life-altering, outcome altering therapy. At that time, we still didn't know that. And here I was as a neurology resident getting to interview an up-and-coming clinical trialists in the field about something that eventually would be groundbreaking. And that was all because of Ted and the podcast in that original 2009 interview. And so that's really cool.
I wonder if Dr. Khatri remembers that interview as well. We were probably both nervous at that time.
Dr. Stacey Clardy:
Now you're old pros. I suppose you touch on a little bit of the brilliance there too, interviewing the authors themselves many times who were just as shy and nervous as we were. And we take this for granted now, but there's a reason why this is brilliant because if the questions are framed correctly, the art of it, the conversation gives you so much that isn't in the paper, and it brings the author's expertise right into your living room. I don't know about you guys, but this is where mid-interview now that we all have so many interviews under our belt, this is where in the middle of the conversation, I'll just take it off the rails now because without fail, the people we're interviewing always say something fascinating. It usually, in my mind, goes right back to a patient I've seen or a question I have. And you've got the expert on there and you can ask them.
You can say, "Yeah, I know this isn't in your paper," but that is really the brilliance that all of us were taught and learned. I don't know what your thoughts are here, Jeff, if you remember the first time this was happening or even recently when this happened to you.
Dr. Jeff Ratliff:
So one of the other lessons that I keep in mind when we're talking with the authors is it's so important to them that they bring all the context, they've done the background research, they've done the work leading up to the publication. But it's critical to them that the listener and we in neurology can understand what's going on with the project and why it's important. And I remember it was 2019 and I was doing an interview with Michael Fox. We were talking about his work doing brain lesion mapping to try and understand dystonia. And I'll admit, I was maybe even struggling a bit in the moment on how to take these concepts of brain connectivity and brain lesion mapping, and to bring it into the clinical sphere and to make sure our listeners understood what we were trying to do.
And I ask a question and he gives an answer. And then he says, "You know what would be a great question to ask?" And right off the cuff, and I wish I could remember it, he formulates this question and he said "Then we could talk about this." And his advocacy to make sure that we took this opportunity to bring the topic to the listener and make sure that we could understand it this way.
So if you ask me this and then we could do it this way and the collaborative nature of working with the authors is really valuable. Because we say this amongst ourselves all the time that we want them to sound good, but we want them to have that opportunity to teach the audience about their work and why it's important. It stuck with me that he and I had the same goal in that interview.
Dr. Stacey Clardy:
I remember that interview really well. I'm not sure that the paper would've gotten me there and there's no place as an author of a paper to put in why it matters, why you should read it, why you should care. That's just not how we structure scientific writing. And we've played with a lot of ways to do this, ways to bring the messages to different components of the audience because we're so fortunate. It's a huge international audience and it's everyone from patients to trainees to world experts in neurology. And so we've had so many format changes over the years.
You guys were sharing your first interviews. I was fortunate when I came in, I was able to get started doing resident and fellow clinical pearls, which were much easier than being thrown into the deep end and interviewing a world expert. And so many people remember those when we had the resident and fellow clinical pearls.
That was when the podcast had broken up different segments. Often there was a lesson of the week in there as well. Somewhere back in there is when we brought in Delayed Recall, which we still have kept and feature separately.
Andy, which part of that history and the different segments do you remember? And I guess is there a format you'd be tempted to bring back or introduce?
Dr. Andy Southerland:
Yeah. And one thing again with Ted that he instilled in those of us who continued on the podcast, and Stacey, you've continued to do it well with Jeff and folks today, is to constantly be thinking about ways we can do it differently to never becomes stale, particularly when you're talking about a medium like a podcast. So we have changed the format around a bunch and to see what sticks, what works, what doesn't work. You mentioned the Delayed Recall, which incorporated something we used to call lesson of the week. We would bundle a group of topics or podcasts around a certain topic. And that was really popular over time.
And I like that because you could really touch on say a given disease from a lot of different angles. And we were asking about some of the most memorable podcasts, and I specifically remember a Delayed Recall series on Lewy body dementia where we were interviewing someone who had written a primary research article on the Journal of Neurology, which was of course very interesting from a clinical neurology and a neurology research perspective, but we bundled it with an interview with Susan Schneider Williams about her husband, Robin Williams in the book.
And it really just adds a complete other layer of context to the diseases that we treat. And that particular format of the podcast really allowed for that well. And it was very interesting to the listeners and I'd be tempted to bring that back.
Of course, you also know one of my favorite series is a series we still do from time to time, which is the Physician as Patient series. And that's really been impactful to talk to some of our own colleagues about the experience of being a patient and dealing with neurological disease. And so it's really been fun to see all the dynamic ways that we can bring life through the podcast to what we do day in, day out.
Dr. Stacey Clardy:
Yeah. I remember the Susan Schneider Williams interview vividly. I remember where I was driving on my commute when I listened to it the first time because it was a lightning bolt moment for me where I was able to synthesize what I had been taught and seen in residency about dementia with Lewy bodies. But the nuance and how to make the diagnosis was what I learned from her because she talked about the sequence of symptoms that Robin Williams had, and things that simply just weren't captured in my formal education, whether written or in the clinics. From that interview, I incorporated questions that I use to this day when I'm assessing someone and I'm suspicious for dementia with Lewy bodies. So I do remember that vividly.
And of course, yes, the Physicians as Patient series that we continue that's also at the annual meeting is incredibly impactful to all of us across the board.
We're going to stop right there for now and we'll pick up with part two of this podcast with Jeff, Jason, and Andy talking about the history of the podcast and the secret sauce, and what matters most in the second part of this series. Please join us for the next episode.
This is Stacey Clardy, your podcast editor. If you've enjoyed the podcast, please take a few moments to subscribe, rate and review the Neurology Podcast through Apple Podcasts, Google Podcasts, Spotify, or wherever you listen.
And remember, you can always head to neurology.org/podcast for our full list of past episodes, or you can also search by keyword in your podcast app for any neurology specific topics you want to learn about. - In the second episode of this two-part series, Dr. Stacey Clardy talks with Dr. Justin Abbatemarco about the risks of immunosuppression for autoimmune neurologic diseases and how to optimize the benefits of immunotherapies while minimizing the associated risks.
Read the related article in Neurology®.
Disclosures can be found at Neurology.org.
________________________________________________
Dr. Jose Merino:
This is Jose Merino, editor-in-chief of the Neurology Family of Journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening, and have a great week.
Dr. Stacey Clardy:
This is Stacey Clardy from the Salt Lake City VA, back with part two of our Bugs and Drugs in the B-cell Era Depletion podcast with Justin Abbatemarco. We're talking about things that have come to the forefront in terms of infections and how they present and how to prevent them in B-cell depleted patients, but also as it applies to folks with immunocompromise of all varieties. We discussed specifically the Potosi virus in part one, and here we're going to talk more broadly about common viruses that our patients encounter and how we address this, what we can do to prevent things, and cautions around making sure patients are vaccinated, but being careful with those live vaccines as well. I hope you enjoy. Justin, how do you approach, first of all, anti-CD20 dosing, or what can you do to mitigate the effects of any therapy? And how do you feel about the possible role of immune globulin treatment here?
Dr. Justin Abbatemarco:
It's such a challenging scenario, and sometimes asking for some help with our colleagues, allergy and immunology is a big part of our practice here. And asking whether or not possibly supplementing with IVIG, if especially their IG levels are low, is something to at least think about. As you've talked about in the podcast many times, we should get all of the samples that we need, both in serum and CSF before initiating IVIG because it can cloud all of those results. And so saving those samples beforehand. And also again, acknowledging that there's not great data to help support this. Maybe the best data is within the West Nile literature that it's possible IVIG, especially if it's pooled around that area, might have relevant autoantibodies to help that patient fight off infection, and was published in some of the reports you've already mentioned. And to see if that would offer any chance, again, in these really challenging spots where we don't have effective vaccinations, we don't have effective antivirals, and how are we going to help patients? It's a multidisciplinary discussion. How do you think about it in your practice?
Dr. Stacey Clardy:
The same, really. We're in autoimmuneology, so we're accustomed to having discussions where there isn't high-quality data. We all are equally frustrated by the fact that usually at best we can discuss low-quality case series, retrospective studies. And so I explain that whole concept of what I'm coming to the table with, to the family and to the patient, and say, "This is low-quality data. I want you to know that," so that they understand the level I'm presenting and the level they're making a decision with. Of course, yes, always preserving those samples and the ability to hopefully find out in the future more of what's going on.
But when you're in the hospital, when you're ill, when you're decompensating, those specific patients, yeah, certainly we have for West Nile cases given intravenous immunoglobulin as part of supportive care, but full well acknowledging to everyone, the family, the patient if they're well enough, the teams, this is a bit of a Hail Mary, and it's theoretical, just hoping that particular donor pool might be able to offer some prior infectious exposure immunity to the patient that's receiving that. So yeah, pretty much the same as you, I would say.
And you're making me think back to what you said about vaccines. That's a fraught discussion and one where I have had to do a lot of education to two big points that I always have to refresh on. One, we can't do live vaccines after they're on that B-cell therapy. And the other one is counseling patients on what vaccinations actually do. And this one's coming up now because here we are November. So I've been having the influenza vaccine talk at every single visit. And many patients say, "Okay, I'll get the flu shot because I don't want to get the flu."
And I immediately pause the conversation, and I say, "Look, that's not what this vaccine does. You are still going to get the flu if you're exposed to the flu virus in the sufficient environment, in the sufficient amount." I say, "Our goal here," particularly for those on immunosuppression, "our goal here is that if you are vaccinated, we hopefully keep you out of the hospital. We're hopefully lessening the severity of the infection that you are going to get if you're exposed in the appropriate setting." And it's amazing to me that the large majority of folks forget that. I don't know if that's your experience.
Dr. Justin Abbatemarco:
The same exact experience. I wish I could just have my answer on a loop just so I could help, but it's an important conversation we have to have. The other thing that came to mind was patients saying that before they were on treatment, "I never got the flu and so I don't need the vaccine," and trying to shift their mindset to be like, "Absolutely, hear that, but your risk profile has profoundly shifted now." We've got to change that thought process a little bit. And yes, that when you get the vaccine, you might not feel well for a few days, but much better than going to the hospital or even worse outcomes that we know can be associated with flu and other bugs.
Dr. Stacey Clardy:
And particularly around the holidays, it becomes a perfect storm. And so I do try to acknowledge this in some of our conditions more than others that I jokingly say, "Hey, you have a doctor's note from me not to spend any time with anyone who stresses you out around the holidays." Because it's also that everything that happens when people holiday, so sleep disruption, poor diet, and probably most importantly, the emotional stressors that have impacts on the immune system that we don't even begin to understand, except that we see it. We see that patients do worse with autoimmune conditions when they take those emotional hits. I believe my patients, they go to a stressful funeral, and that's their first symptom.
So I try to give them this whole package of a talk and say, look, if they stress you out anyway, if they tell you they have a sniffle, that's a no-go because you put the perfect storm together, you're going to get sick, even if you do some Purell and things like that. So take yourself out of those situations. And usually, it's at least good for a bit of a chuckle from the patients, but also I hope that they're internalizing that into the entire, to your point, lifestyle. This is a different you. This isn't the you that never got the flu before you were immunocompromised. This is a new you and one where you have to pay attention not just to the germs, but the entire setting around that. I don't know if you do anything like that, but it at least helps sometimes, hopefully, to lighten the mood.
Dr. Justin Abbatemarco:
I was going to say, it feels like it's going to become like an in-laws talk. I don't know how those conversations to help or is the smart phrase in the letter being like avoid your in-laws.
Dr. Stacey Clardy:
Rough. Poor in-laws. Everybody's an in-law. Yeah, no, same. Going back to your original case and the things that are going to perturb all of us deeply about that, being that the onset was not dramatic, this was not a patient that landed in the ICU after going out hiking, what are you doing now? What do you advise we do when someone on an anti-CD20 therapy or other significant immunosuppression develops otherwise unexplained cognitive or behavioral decline? What's the one thing you really want us to learn and do differently after that particular presentation of a virus?
Dr. Justin Abbatemarco:
Some themes that we've hit on and things I've incorporated in my practice is that moving away from these traditional risk factors that I would've previously associated with CD20s, so age, time on therapy, their disability, their IgG levels. Yes, those are some markers that we could use, but I will not be married to those to think about their risk of infections on these classes of medications. I think two, the CD20s can really mask the degree of inflammation that we can see or the serologies. And so being a little mindful of how we incorporate testing and maybe a little sooner metagenomic next gen sequencing if we can get that in the spinal fluid. And again, just having this higher on that differential and being a little bit more mindful about prevention, and all the different ways we talked about. Those are some things that we're really going to think about, and hopefully help our patients and family members moving forward.
Dr. Stacey Clardy:
Yeah, these are great points. And now you've just made me think of something else. All these ghosts of patients past good syndrome. I know you're familiar with that, but again, it's not just the CD20 patients, it's these patients walking around who don't know that their immune system is not normal. And I've been involved in the care of several folks now with good syndrome. And so what is that? They don't teach us what that is in neurology, but it's an immune deficiency. And these folks can also be hovering around our clinics with things like myasthenia gravis and other unusual autoimmune conditions.
And those are the patients that really drove home for me asking the infectious exposure questions, the infectious history, sinus infections, bronchitis, urine infections, skin infections, the hangnail that didn't heal, or, oh, just a little bit of MRSA, but it healed up, those things all together because those patients essentially have really an undiagnosed immune deficiency that causes frequent infections that some may not recognize are too frequent, superimposed with autoimmunity. And if we don't pick up on them because they come in and we're going to treat the autoimmunity, goodness, we've really doomed them to some awful things too.
And so there are other reports out there, other than the Potosi virus, and some of those reports are in these patients of just really being unable to clear viruses chronically from their brain. So it really is a great example of caution for me on these medications, but also just listening to those patients and caution in any patient that comes in where it doesn't quite sound right. As you said, she was young. There was nothing right out of the gate except why the cognitive changes, why this stuff. And I think they're out there more than we realize. CD20 agents are going to bring them to the forefront, but this still occurs naturally as well.
Dr. Justin Abbatemarco:
I'm guessing you picked up some of those cases, like good syndrome, by doing testing before you started immunosuppression?
Dr. Stacey Clardy:
I have. So things to think about, especially, we didn't even talk about this, but measles titers and measles vaccination, what do we do with that in rituximab? That's a live vaccine. So we can check our patient's IgG, which is again only half the story. For example, you may get a low IgG, and they may actually have some immunity on that titer because, depending on the rituximab or the other B-cell agents, how long they've been on it, but it's a good reminder.
That's a discussion that I've been incorporating as well, especially in the last one to two years. What's your measles status? Were you vaccinated? How many times were you vaccinated? How old are you? Meaning, how did that inform the vaccine strategy when you were younger if you did? And if you didn't, again, that extra layer of, oh, this is serious. Are you a teacher? Are you a healthcare worker? What area of the world do you live in, and how much are we seeing resurgence of measles? I don't know if that's come up in your clinic, too.
Dr. Justin Abbatemarco:
It has, and I agree. It's just such a difficult conversation. People aren't usually aware. I appreciate your comment. The measles lab test is imperfect, so that's not a great marker. And then a live vaccination, have to be thinking about this before you open this door, maybe a Pandora's box with these immunosuppressive medications, but it's such a difficult topic to explore with patients and their families.
Dr. Stacey Clardy:
The one we have to explore. That much is clear. That's our job. If we're ever writing a script for an immunotherapy, we've got to discuss all of these things and be thoughtful and give patients references for them. In the era of the electronic medical record, this is very easy to incorporate all of these things. Justin, it has been a great review for me and learning. Thank you for walking us through all these scenarios, things to think about. This helps me to continue to shape my approach in clinic, and this two-part podcast has been thought-provoking. So thank you for that, and thank you for publishing your paper. The title again is Establishing Potosi Virus as a Human Pathogen: Fatal Neuroinvasive Disease in a B-Cell Depleted Patient. It is in Neurology. Thanks, Justin.
This is Stacey Clardy, your podcast editor. If you've enjoyed the podcast, please take a few moments to subscribe, rate, and review the Neurology Podcast through Apple Podcasts, Google Podcasts, Spotify, or wherever you listen. And remember, you can always head to neurology.org/podcast for our full list of past episodes, or you can also search by keyword in your podcast app for any neurology-specific topics you want to learn about. - In part one of this two-part series, Dr. Stacey Clardy talks with Dr. Justin Abbatemarco about why infection can be overlooked in people on anti-CD20 therapy and practical ways clinicians can improve testing, prevention, vaccination, and collaboration with laboratories and infectious disease specialists.
Read the related article in Neurology®.
Disclosures can be found at Neurology.org.
_______________________________________________
Dr. José Merino:
This is José Merino, editor-in-chief of the Neurology Family of Journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening and have a great week.
Dr. Stacey Clardy:
This is Stacey Clardy from the Salt Lake City VA and the University of Utah with a two-part neurology podcast. Today, we're talking about infections, specifically in people receiving anti-CD20 therapies, but also good food for thought and folks who are otherwise walking around immunosuppressed. And there's a case that inspired this podcast.
So joining me to talk about that is Justin Abbatemarco from the Cleveland Clinic. You know him well as one of the voices of the podcast. He's also an autoimmune neurologist and he's the author on this report. The title of the report is Establishing Potosi Virus as a Human Pathogen: Fatal Neuroinvasive Disease in a B-Cell-Depleted Patient. Justin, thanks for agreeing to be interviewed today instead of leading the interview.
Dr. Justin Abbatemarco:
It's much less comfortable on this side of the mic, Stacey.
Dr. Stacey Clardy:
Yes. Yes, it is. But hey, we're all friends, so we'll just chat. So Justin, your report establishes that Potosi virus, which I have never heard of, can cause fatal encephalitis in humans. So what is this virus and what do I need to know about it? And what is this case teaching us, especially with our increased usage of all these B-cell depleting agents?
Dr. Justin Abbatemarco:
This was a really humbling case that we had in service, and I think we have much more to learn about Potosi virus and its interaction with humans and immunocompromised hosts. This is only the second report and the only one with pathology to help confirm it. But the virus has been known for a really long time. It's been documented mosquito populations before this, but it's only been over these last few years that it's been linked with metagenomic next gen sequencing as a potential human pathogen.
And so more to come. We really hope this report will spur further investigations on this, have this included as a human pathogen on metagenomic next gen sequencing reports. But I think the bigger thought process around here, it made us really think about it at our clinic on how we approach patients on CD20 medications or their immunosuppressive medications. Because the way this case presented initially, it really threw us. Infection was not on the top of our differential. And so some of the learning points about the traditional risk factors and how we think about testing, those are some major takeaways we had when we look back at this.
Dr. Stacey Clardy:
So tell me about this. What did you think was going on? I read that her MS seemed to be fairly well controlled on a B-cell depleting agent. So how did she present so that it can scare me even more that I'm missing this?
Dr. Justin Abbatemarco:
I know, it's so humbling. But she was 37, she was diagnosed with MS over a decade ago. She had been on some of our platform medications and in 2020 started rituximab and did incredibly well. Minimal disability on examination. IgG levels were normal.
She actually worked in our hospital and by about four years on therapy, she starts developing some subtle symptoms, feels like she's having a hard time with attention processing, things we hear about all the time in clinic.
Dr. Stacey Clardy:
Yeah.
Dr. Justin Abbatemarco:
Everything looks stable from an MRI perspective, so we continued along. But a few months into that course, she's unable to maintain employment. She had severe neuropsychiatric deficits. So we brought her into the hospital, extensive evaluation. The only thing that popped forward was that she had six cells on her spinal tap. All the conventional studies for autoimmune diseases, other infections, even prion diseases were evaluated and nothing came up.
Over those coming months, I think what stood out was that her MRI showed this dramatic global atrophy and the paper, the figure will do better than anything I could describe in words, but some of the measures including her whole brain atrophy measures were just off the charts, which is just not typical of MS at this point. And eventually we were able to get metagenomic next gen sequencing, which identified this virus. And then through the work of many people to get this report across, including our colleagues across the CDC and many across the Cleveland Clinic research campus, were able to prove that the virus was within the neuron and likely drove the cause of death here.
Dr. Stacey Clardy:
So some of this was postmortem on that brain tissue, is that right?
Dr. Justin Abbatemarco:
Definitely, just because there hadn't been proven on pathology before. So I think that was a really important part of this case. The previous case report had just mentioned this on metagenomic next gen sequencing, but left open the ultimate cause of death.
Dr. Stacey Clardy:
And you can of course see the images and you should go do that. This is published in the Green Journal. You raised the point that it wasn't so much the dramatic white matter changes, it was atrophy. Is that right?
Dr. Justin Abbatemarco:
Yes. Without other evidence of inflammation within the CNS space, six cells was just one over the reference range, just not the dramatic presentation we expect with a CNS infection.
Dr. Stacey Clardy:
And you said her IgG was normal at her last rituximab infusion, is that right? Because that's usually a marker we look at to say, "Oh, maybe this is someone who's susceptible." But her IgG was normal?
Dr. Justin Abbatemarco:
Yeah, before the onset of these symptoms was normal. The other risk factors I think about too, age, she was 37, minimal disability on examination. Her EDSS was one to two. And so those traditional risk factors that are in my mind and when I'm counseling patients, she had none of those.
Dr. Stacey Clardy:
But then down the road you said her IgG did drop, but that was after this virus took hold, right? So in other words, it didn't protect her having a normal IgG. Is that fair?
Dr. Justin Abbatemarco:
She was also on lots of other medications that could have confounded the IgG level. I know you've talked about that a lot on the neurology minute, and so it was a little harder to interpret through the course of her hospitalizations.
Dr. Stacey Clardy:
So not specific to her, but yes, to your point, there are multiple medications we give in the course of someone's illness, right? Sometimes we give anti-seizure medications or really potent antipsychotics or even high dose methylprednisolone and all of those things can lower IgG and then it becomes a chicken-egg phenomenon, right? So not necessarily specific to this patient, but I understand what you're saying.
So with that in mind, you eventually identified this Potosi virus through the metagenomic sequencing of the CSF. Now that you have a result like this, now that you've lived through this tragic case, has this unusual and presumably quite rare result changed how you would send that test in another patient, your threshold, how soon, or are you saying this was a super rare event, maybe not? What has changed in how you practice?
Dr. Justin Abbatemarco:
Utilizing that test, especially within our autoimmune neuroimmunology population who are commonly immunocompromised, we're going to have a lower threshold to send that off. And we've discussed this in the podcast so many times about the pros and cons of that test, that it's definitely not a silver bullet, but it's particularly helpful in patients who are immunocompromised. And so despite that she didn't have a huge CSF pleocytosis initially and that we weren't sure exactly which bug we were looking for, early evaluation with metagenomic next gen sequencing is something we're going to think about.
Dr. Stacey Clardy:
And in select cases, certainly this sort of presentation doesn't come along all the time, but I'm old enough now and many folks, if you've been practicing neurology, if you did your internal medicine here, if you're at all in the hospital, we all have what I call the ghosts of patients past.
I've certainly seen some patients where we never found a pathogen via all the traditional measures and yet you knew in your core that was the top thing going on. So not a ton of patients, but certainly we all can think of ones where we never quite got to the diagnosis. And we've talked to Avi Nath before too at NINDS, and he also tells us that you can remain negative, even sometimes on the next generation sequencing and ultimately tissue pathology is the only way you can make the diagnosis.
Let's talk about some of the more common things that we should be looking for in patients who are on B-cell depleting therapies or otherwise have an inborn error of immunity or acquired immunodeficiency. I'm thinking of another paper by banks and colleagues about enterovirus. The title of that paper is Enterovirus Encephalitis in People With Multiple Sclerosis on Ocrelizumab: Insights From a Multicenter Case Series. And I imagine you're familiar with that as well, certainly with the research for this case report.
So in that five patient series, how do you compare, contrast that to this one? What stood out to you there about exposures and how the patients presented with enterovirus?
Dr. Justin Abbatemarco:
Doing some research for this case report, diving into this literature, enterovirus, really common. One of the more common causes, encephalitis, common with our pediatric population for acute facet myelitis. So it's been out there. And then this case report did highlight that the potential of a severe course with patients with CD20 exposure.
And again, some of those same themes in terms of only a few years on this treatment, two, three, five years, that constitutes a huge portion of our clinic. And so these weren't patients that were on it for a decade plus. They were younger, again, with less disability than I would've considered. And then also had this protracted course that was not immediately bringing to mind an infection, and it took a little time for them to get to the ultimate diagnosis.
And then these patients didn't have great outcomes either. And so this constellation, I really had to shift my mindset of just being like the traditional risk factors I had thought about with CD20s and infection risk, that they're imperfect to really be mindful of that as patients come to clinic with new symptoms, new MRI changes, and to keep that differential broad.
Dr. Stacey Clardy:
Yeah. And that paper, if I didn't mention it, is published in N2. In there, I was struck by the fact that four of those patients had recently ill young children, including two cases of hand, foot, mouth. And I balance this in my head now with these therapies are so incredible, especially the volume we see them in with multiple sclerosis patients, but also with the other rare diseases, NMO, autoimmune encephalitis.
And so often I'm saying to patients with these therapies, you don't have to worry about the things we worried about 10, 20 years ago. You're going to be able to live your life normally. And then I look at these cautionary tales and go, "Oh, but these are healthy people who are having children, so they are going to be exposed to this sort of stuff." And so I've started to maybe temper even more among the discussions and especially around holiday seasons, for example.
And I say, really just tell anyone who wants to visit if they have a sniffle, if they had a GI bug and they say, "Oh, but I've been better for two days." Any of those sorts of things saying, "Hey, just come over in a week. Oh, let's just do that in a few more days." Because the non-immunocompromised population really doesn't think in terms of could they still be spreading an illness?
And these are people with full active lives and all the exposures, right? I'm sure you have just the patients I do, and you mentioned in your case, many patients on these therapies are healthcare workers, they are teachers, they are parents. And so what more can we do, I wonder, to caution them? I already give them all my talk about carrying Purell at all times, about wiping down surfaces, especially airplanes or public places with some Lysol wipes, things like that. What else do you do?
Dr. Justin Abbatemarco:
I think that idea of how to balance this conversation, this is a challenge I face every day in clinic because I'm trying to walk people off the edge. They get these life-changing neurological diagnoses and they want to go into a bubble and the CD20 class, other classes of medications have allowed patients to live full and fulfilling lives with these diseases.
And then balancing now with this literature that they can have these really serious adverse events related to these infections. I'm struggling with that same messaging, but I do think I've been more cautious and going beyond just what's been reported in the literature on UTIs and upper respiratory infections that the spectrum of illness that we can see with these medications is maybe clearer than we had initially thought.
And so that's been something I've been trying to do to thread that needle with patients and family members about this, but I love your couching around how to talk to friends and family in a practical way. One strategy that we've worked hard, and again, been more mindful over the last few years has been vaccinations. I think rheumatology has been ahead of us in terms of their guidelines and how they implement this, but this has become more of a routine part of our practice.
We've had pharmacy integration to really help guide this, but outside of just our age appropriate seasonal vaccinations to talk about other vaccination strategies, including pneumonia and shingles. For these cases, RSV has come out now for our older population, and so really making sure that's a part of the conversation at every visit. How do you handle those conversations in your clinic?
Dr. Stacey Clardy:
Same. And what I've found out practically speaking, at least in the United States, is when you send these patients to pharmacy or to even primary care settings, you really have to take care to thoroughly document in no uncertain terms in the note, this patient does not qualify by age, they qualify by immune status, and it really is another extra ordeal often with insurance companies covering those vaccines for these patients.
As our practice has changed, as we've gotten access to these tools, I really think we have an imperative here. You can't be prescribing these B-cell therapies unless you're willing to take on that work, which is to take ownership of the vaccination, take ownership of the baseline immune testing. Your case points out to us that it's not perfect. We're still going to miss some susceptibilities, but before we're touching these patients, assessing that immune system as in depth as we possibly can, it goes a little beyond the scope of our conversation, but I've found inborn errors of immunity in patients who have a new NMO diagnosis, a new MOG diagnosis, a new NMDA receptor encephalitis diagnosis, and of course in those multiple sclerosis patients too.
And you really only get one chance to assess for that rigorously, and that's before we bring out these therapies. So I suppose maybe that's one standard we can hold ourself to. Should you be prescribing these unless along with that, 100% of the time you are doing the vaccinations, you're assessing the immune status of the patient, because it's easy to have that get lost in these conversations even if we have long appointments, right?
Dr. Justin Abbatemarco:
I totally agree. And good lab testing ahead of time discussions. One other piece that the CDC talked about tick and mosquito bite prevention.
Dr. Stacey Clardy:
Yes.
Dr. Justin Abbatemarco:
That was never something that was a part of my conversations.
Dr. Stacey Clardy:
Yes.
Dr. Justin Abbatemarco:
And global warming and climate change has probably moved these bugs into larger geographical areas. And so that's another thing. Again, not putting them in a bubble, but at least talking about maybe wearing some long sleeve shirts, long pants when they're outside, other strategies including sprays and things to minimize their risk. Another piece to this discussion that I was never having before this.
Dr. Stacey Clardy:
And there's actually two papers I found. One is by Kapadia and colleagues. The title of that is Severe Arboviral Neuroinvasive Disease in Patients on Rituximab Therapy: A Review, that's published in Clinical Infectious Disease in 2023. And then there's another one. The title of that one is Tick-borne Infections in Patients Under Anti-CD20 Therapy: Challenges for Diagnosis and Treatment, that was published in multiple sclerosis in 2025. Both those papers reinforce this.
Dr. Justin Abbatemarco:
That's another piece of this that we didn't talk about on our original case that rituximab has all these risks, but they also impair the testing when you're looking for these bugs, especially those based on serologies. And another caveat, so we talked about metagenomic next gen sequencing and its benefits, but it has some limitations when it's looking for bugs that are best detected with serologies, partnering with ID to really think through that, consideration of repeat testing if you really think that's the bug where we probably traditionally wouldn't do that. Those are some approaches we've had. And then again, that partnership is so important.
Dr. Stacey Clardy:
What I've learned over the years too is if you call the folks who are doing this testing, the metagenomic next generation sequencing, even if it flags negative, you're in a position where you have a candidate bug, I've called them and say, "Hey, do you see this? And if you see it, is it just below threshold? I want to let you know this is an immunocompromised patient."
And they will then apply different filters to the review of it. And I found those folks to be very helpful. It sort of reinforces something we say here a lot, like for goodness' sake, call your laboratory partners. They want to help. They're one phone call away. And I do recall in that case, that was how we ultimately ended up securing the diagnosis was really, as you said, by calling for help. And in that case, not just infectious disease, not just immunology, but also frankly, the folks who were running the tests.
Dr. Justin Abbatemarco:
It takes a village. And the only reason the Potosi virus was discovered was because our infectious disease doctor was on the original publication and worked with the lab to report this out because otherwise this isn't a known human pathogen. It wasn't going to be reported as a relevant result because they usually subtract those bugs that they find as non-relevant. And so many examples of how that additional context allows the lab to interpret these results in more profound way.
Dr. Stacey Clardy:
Yeah. Wow. Justin, let's stop part one of our discussion on that point because it's such an important point about speaking up when the existing practice or methodology could fail an immunocompromised patient. We'll continue talking about the benefits and the real risks of immunosuppression for autoimmune neurologic disease in part two. So please join us for more on how to maximize the benefits of immunotherapies while minimizing the risks. Thank you.
This is Stacey Clardy, your podcast editor. If you've enjoyed the podcast, please take a few moments to subscribe, rate, and review the Neurology Podcast through Apple Podcasts, Google Podcasts, Spotify, or wherever you listen. And remember, you can always head to neurology.org/podcast for our full list of past episodes, or you can also search by keyword in your podcast app for any neurology specific topics you want to learn about. - In this special conversation, recorded live at this year's AAN Annual Meeting, Dr. Alison Christy talks with Drs. Franziska Herpich and Yolanda Holler-Managan about how personal experiences with stroke, disability, and caregiving have changed the way they understand and care for patients and families.
Listen to the previous episode featuring Dr. Franziska Herpich.
Disclosures can be found at Neurology.org.
Más podcasts de Ciencias
Podcasts a la moda de Ciencias
Acerca de Neurology® Podcast
The Neurology Podcast provides practical information for neurologists and clinicians to practice the best possible medicine for patients. Examining methods and findings in peer-reviewed journals, the show provides insights that impact clinical practice and patient care. From the journal Neurology and the American Academy of Neurology, providing education and expert analysis since 2007.
Sitio web del podcastEscucha Neurology® Podcast, Jefillysh: Ciencia Simplificada y muchos más podcasts de todo el mundo con la aplicación de radio.net

Descarga la app gratuita: radio.net
- Añadir radios y podcasts a favoritos
- Transmisión por Wi-Fi y Bluetooth
- Carplay & Android Auto compatible
- Muchas otras funciones de la app
Neurology® Podcast: Podcasts del grupo








































